Back

Cerebral microbleeds and acute coronary syndrome: screening and progression under dual anti-platelet therapy: proof of concept study

27 August 2018 (15:15 - 15:30)
Organised by:
Congress Presentation Part of: Bleeding complications in ACS Pathophysiology and Mechanisms, Other ESC Premium Access ESC Congress 2018

About the speaker

Photo
Mr Abbass Alaaeldin

University Hospital Center, Dijon (France)

4 More presentations in this session

Presentation thumbnail
Differential prognostic impact in mortality of myocardial infarction compared with bleeding severity in contemporary acute coronary syndrome patients
Mr R. Cobas Paz (Vigo, ES)
Abstract Slides Video
Presentation thumbnail
Impact of prior stroke on acute myocardial infarction: population characterization and influence on in-hospital mortality and complications
Doctor M. Carrington (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Differences in the ischemic-hemorrhagic balance between diabetic and non-diabetic patients treated with dual antiplatelet theraphy with ticagrelor and prasugrel
Mrs M. Castineira Busto (Vigo, ES)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes following percutaneous coronary intervention among patients with cancer: observations from a large unselected cohort
Doctor Y. Ueki (Matsumoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Bleeding complications in ACS

The Event

Event poster

ESC Congress 2018

27 August 2018 15:15 CET
You may be interested in
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
28 August 2023
thumbnail
Congress Presentation
Patients with carotid intraplaque hemorrhage have higher incidence of cerebral microbleeds
28 August 2022
thumbnail
Congress Presentation
Microbleeds in patients with heart failure and atrial fibrillation
12 April 2026
thumbnail
Congress Presentation
Outcomes of dual antiplatelet therapy in combination with direct oral anticoagulants in patients with acute coronary syndrome: a meta-analysis
28 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources